# FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

> **NCT05304962** · PHASE1 · RECRUITING · sponsor: **Regor Pharmaceuticals Inc.** · enrollment: 64 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** RGT-419B
- **DRUG:** RGT-419B in combination with hormonal therapy

## Key facts

- **NCT ID:** NCT05304962
- **Lead sponsor:** Regor Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-04
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304962, "FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05304962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*